Auspex Pharmaceuticals Inc. (ASPX) 100.96 $ASPX
Post# of 273257
Posted On: 09/03/2016 7:26:08 PM
Auspex Pharmaceuticals Inc. (ASPX) 100.96 $ASPX
R. Scott Greer Joins Inogen Board of Directors
GlobeNewswire - Thu Aug 06, 7:45AM CDT
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that R. Scott Greer has been appointed as an independent director to its Board of Directors, effective August 3, 2015. In addition, Mr. Greer was appointed to the Board's Audit Committee. He will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held on October 14, 2015. Mr. Greer fills the vacancy created by the resignation of Timothy Petersen. Mr. Petersen had served as a member of Inogen's Board since 2010.
VSAR: 12.48 (-0.67), STEM: 1.54 (unch), INGN: 58.11 (+0.16), ILMN: 167.90 (-0.66), ASPX: 100.96 (unch), NKTR: 18.45 (+0.34), SIEN: 8.22 (+0.06)
Acute Coronary Syndrome Therapeutics Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qf9st8/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Auspex Pharmaceuticals, Inc. - Bayer AG - Esperion Therapeutics, Inc. - GlaxoSmithKline Plc - Lee's Pharmaceutical Holdings Limited - MedImmune, LLC - Pfizer Inc. - The Medicines Company - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles - 4-WF - AEM-28 - AEM-28-02 - Artpep-2 - Biologics for Acute Coronary Syndrome - bivalirudin - cangrelor - COR-2 - COR-3 - gevokizumab - losmapimod - MDCO-216 - MEDI-6012 - MTP-131 - PC-mAb - PF-06282999 - PMC-6 - PR-15 - rivaroxaban - SD-970 - temanogrel hydrochloride - VTP-38443 - ZK-001 For more information visit http://www.researchandmarkets.com/research/qf...e_coronary
ESPR: 10.78 (+0.02), PFE: 34.77 (+0.09), AZN: 33.31 (+0.71), VTAE: 7.01 (+0.17), ASPX: 100.96 (unch), GSK: 44.26 (+1.28), ARNA: 1.57 (+0.01), XOMA: 0.56 (unch)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 90.75 (-0.50), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), ASPX: 100.96 (unch), NVS: 79.38 (+1.11)
Concert Pharmaceuticals awarded USD50m payment from Auspex Pharmaceuticals
M2 - Tue Jun 09, 6:06AM CDT
Concert Pharmaceuticals (NasdaqGM:CNCE) reported on Monday the receipt of USD50.2m from Auspex Pharmaceuticals pursuant to a 2011 patent assignment agreement.
ASPX: 100.96 (unch), CNCE: 9.68 (-0.03)
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 49.44 (-0.68), CPRX: 1.03 (+0.07), AZN: 33.31 (+0.71), ASPX: 100.96 (unch)
Concert Pharmaceuticals Receives $50 Million Payment from Auspex Pharmaceuticals
BusinessWire - Mon Jun 08, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is pursuant to a September 2011 patent assignment agreement between Concert and Auspex whereby Concert assigned to Auspex a U.S. patent application relating to deuterium-substituted analogs of pirfenidone. Under the agreement, Concert became eligible to receive the payment due to a change of control of Auspex, which was acquired by Teva Pharmaceuticals Industries Ltd on May 5, 2015.
ASPX: 100.96 (unch), CNCE: 9.68 (-0.03)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 49.44 (-0.68), BMRN: 95.73 (+0.54), TRGT: 0.96 (-1.25), CPRX: 1.03 (+0.07), ASPX: 100.96 (unch), NVS: 79.38 (+1.11)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 313.59 (+7.56), ASPX: 100.96 (unch), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), GILD: 76.89 (-0.53), CGEN: 7.41 (+0.36), IBIO: 0.59 (-0.02), FGEN: 17.84 (+0.51), CELGZ: 1.18 (+0.05), FPRX: 43.71 (-1.03)
Teva Completes Acquisition of Auspex Pharmaceuticals
BusinessWire - Tue May 05, 8:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the acquisition of Auspex Pharmaceuticals, Inc. (NASDAQ: ASPX) has been completed through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Teva's revenue and earnings growth profile and strengthen its core central nervous system franchise.
ASPX: 100.96 (unch), TEVA: 51.22 (+0.32)
Huntington's Disease Therapeutics - Global Strategic Business Report 2015: Competition in the Global HD Therapeutics Market is Non-existent
M2 - Fri May 01, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4l6pzp/huntingtons) has announced the addition of the "Huntington's Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as: - Alnylam Pharmaceuticals, Inc. - Auspex Pharmaceuticals, Inc. - Intellect Neurosciences Incorporation - Lundbeck A/S - Prana Biotechnology Limited Key Topics Covered: 1. INDUSTRY OVERVIEW 2. HD THERAPEUTICS MARKET TRENDS 3. HUNTINGTON'S DISEASE PIPELINE ANALYSIS 4. RESEARCH BREAKTHROUGHS IN HD ARENA 5. AN OVERVIEW OF HUNTINGTON'S DISEASE 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 25 - The United States (13) - Canada (1) - Europe (
- - France (1) - - Germany (1) - - The United Kingdom (2) - - Italy (1) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/4l...untingtons
ASPX: 100.96 (unch), PRAN: 4.90 (-0.02)
Mylan rejects Teva's $40.1 billion buyout offer
AP - Mon Apr 27, 10:35AM CDT
NEW YORK (AP) — Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company.
TEVA: 51.22 (+0.32), ASPX: 100.96 (unch)
Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
RTTR: 1.41 (+0.13), SPHS: 3.11 (+0.17), ASPX: 100.96 (unch)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 235.96 (-1.80), ACT: 298.98 (-2.94), ASPX: 100.96 (unch), TEVA: 51.22 (+0.32)
Mylan skeptical of rumored Teva bid; hasn't received offer
AP - Fri Apr 17, 4:29PM CDT
NEW YORK (AP) — Generic drugmaker Mylan, citing media speculation that Teva Pharmaceutical may be eyeing it as a takeover target, says it doubts that regulators would approve such a deal and is committed to its current strategy as a stand-alone company.
ASPX: 100.96 (unch), TEVA: 51.22 (+0.32)
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 49.44 (-0.68), CPRX: 1.03 (+0.07), ASPX: 100.96 (unch)
ASPX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Auspex Pharmaceuticals Inc. Concerning the Sale of the Company to Teva Pharmaceutical Industries Ltd.
BusinessWire - Mon Apr 13, 9:58AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) ("Auspex Pharmaceuticals" or "the Company"
in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd.
TEVA: 51.22 (+0.32), ASPX: 100.96 (unch)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Auspex Pharmaceuticals, Inc.
BusinessWire - Fri Apr 10, 5:36PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or "the Company" (NASDAQ:ASPX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Teva Pharmaceuticals Industries Ltd. ("Teva" .
ASPX: 100.96 (unch)
R. Scott Greer Joins Inogen Board of Directors
GlobeNewswire - Thu Aug 06, 7:45AM CDT
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that R. Scott Greer has been appointed as an independent director to its Board of Directors, effective August 3, 2015. In addition, Mr. Greer was appointed to the Board's Audit Committee. He will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held on October 14, 2015. Mr. Greer fills the vacancy created by the resignation of Timothy Petersen. Mr. Petersen had served as a member of Inogen's Board since 2010.
VSAR: 12.48 (-0.67), STEM: 1.54 (unch), INGN: 58.11 (+0.16), ILMN: 167.90 (-0.66), ASPX: 100.96 (unch), NKTR: 18.45 (+0.34), SIEN: 8.22 (+0.06)
Acute Coronary Syndrome Therapeutics Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qf9st8/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Auspex Pharmaceuticals, Inc. - Bayer AG - Esperion Therapeutics, Inc. - GlaxoSmithKline Plc - Lee's Pharmaceutical Holdings Limited - MedImmune, LLC - Pfizer Inc. - The Medicines Company - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles - 4-WF - AEM-28 - AEM-28-02 - Artpep-2 - Biologics for Acute Coronary Syndrome - bivalirudin - cangrelor - COR-2 - COR-3 - gevokizumab - losmapimod - MDCO-216 - MEDI-6012 - MTP-131 - PC-mAb - PF-06282999 - PMC-6 - PR-15 - rivaroxaban - SD-970 - temanogrel hydrochloride - VTP-38443 - ZK-001 For more information visit http://www.researchandmarkets.com/research/qf...e_coronary
ESPR: 10.78 (+0.02), PFE: 34.77 (+0.09), AZN: 33.31 (+0.71), VTAE: 7.01 (+0.17), ASPX: 100.96 (unch), GSK: 44.26 (+1.28), ARNA: 1.57 (+0.01), XOMA: 0.56 (unch)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 90.75 (-0.50), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), ASPX: 100.96 (unch), NVS: 79.38 (+1.11)
Concert Pharmaceuticals awarded USD50m payment from Auspex Pharmaceuticals
M2 - Tue Jun 09, 6:06AM CDT
Concert Pharmaceuticals (NasdaqGM:CNCE) reported on Monday the receipt of USD50.2m from Auspex Pharmaceuticals pursuant to a 2011 patent assignment agreement.
ASPX: 100.96 (unch), CNCE: 9.68 (-0.03)
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 49.44 (-0.68), CPRX: 1.03 (+0.07), AZN: 33.31 (+0.71), ASPX: 100.96 (unch)
Concert Pharmaceuticals Receives $50 Million Payment from Auspex Pharmaceuticals
BusinessWire - Mon Jun 08, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is pursuant to a September 2011 patent assignment agreement between Concert and Auspex whereby Concert assigned to Auspex a U.S. patent application relating to deuterium-substituted analogs of pirfenidone. Under the agreement, Concert became eligible to receive the payment due to a change of control of Auspex, which was acquired by Teva Pharmaceuticals Industries Ltd on May 5, 2015.
ASPX: 100.96 (unch), CNCE: 9.68 (-0.03)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 49.44 (-0.68), BMRN: 95.73 (+0.54), TRGT: 0.96 (-1.25), CPRX: 1.03 (+0.07), ASPX: 100.96 (unch), NVS: 79.38 (+1.11)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 313.59 (+7.56), ASPX: 100.96 (unch), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), GILD: 76.89 (-0.53), CGEN: 7.41 (+0.36), IBIO: 0.59 (-0.02), FGEN: 17.84 (+0.51), CELGZ: 1.18 (+0.05), FPRX: 43.71 (-1.03)
Teva Completes Acquisition of Auspex Pharmaceuticals
BusinessWire - Tue May 05, 8:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the acquisition of Auspex Pharmaceuticals, Inc. (NASDAQ: ASPX) has been completed through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Teva's revenue and earnings growth profile and strengthen its core central nervous system franchise.
ASPX: 100.96 (unch), TEVA: 51.22 (+0.32)
Huntington's Disease Therapeutics - Global Strategic Business Report 2015: Competition in the Global HD Therapeutics Market is Non-existent
M2 - Fri May 01, 8:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4l6pzp/huntingtons) has announced the addition of the "Huntington's Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as: - Alnylam Pharmaceuticals, Inc. - Auspex Pharmaceuticals, Inc. - Intellect Neurosciences Incorporation - Lundbeck A/S - Prana Biotechnology Limited Key Topics Covered: 1. INDUSTRY OVERVIEW 2. HD THERAPEUTICS MARKET TRENDS 3. HUNTINGTON'S DISEASE PIPELINE ANALYSIS 4. RESEARCH BREAKTHROUGHS IN HD ARENA 5. AN OVERVIEW OF HUNTINGTON'S DISEASE 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 25 - The United States (13) - Canada (1) - Europe (
- - France (1) - - Germany (1) - - The United Kingdom (2) - - Italy (1) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/4l...untingtons ASPX: 100.96 (unch), PRAN: 4.90 (-0.02)
Mylan rejects Teva's $40.1 billion buyout offer
AP - Mon Apr 27, 10:35AM CDT
NEW YORK (AP) — Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company.
TEVA: 51.22 (+0.32), ASPX: 100.96 (unch)
Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
RTTR: 1.41 (+0.13), SPHS: 3.11 (+0.17), ASPX: 100.96 (unch)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 235.96 (-1.80), ACT: 298.98 (-2.94), ASPX: 100.96 (unch), TEVA: 51.22 (+0.32)
Mylan skeptical of rumored Teva bid; hasn't received offer
AP - Fri Apr 17, 4:29PM CDT
NEW YORK (AP) — Generic drugmaker Mylan, citing media speculation that Teva Pharmaceutical may be eyeing it as a takeover target, says it doubts that regulators would approve such a deal and is committed to its current strategy as a stand-alone company.
ASPX: 100.96 (unch), TEVA: 51.22 (+0.32)
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 49.44 (-0.68), CPRX: 1.03 (+0.07), ASPX: 100.96 (unch)
ASPX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Auspex Pharmaceuticals Inc. Concerning the Sale of the Company to Teva Pharmaceutical Industries Ltd.
BusinessWire - Mon Apr 13, 9:58AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) ("Auspex Pharmaceuticals" or "the Company"
in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. TEVA: 51.22 (+0.32), ASPX: 100.96 (unch)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Auspex Pharmaceuticals, Inc.
BusinessWire - Fri Apr 10, 5:36PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or "the Company"
(NASDAQ:ASPX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Teva Pharmaceuticals Industries Ltd. ("Teva" . ASPX: 100.96 (unch)
(0)
(0)Scroll down for more posts ▼